𝔖 Bobbio Scriptorium
✦   LIBER   ✦

CV205–502, A NEW NON-ERGOT DOPAMINE AGONIST, REDUCES PROLACTINOMA SIZE IN MAN

✍ Scribed by P. S. BARNETT; J. M. DAWSON; J. BUTLER; P. B. COSKERAN; J. J. MACCABE; A. M. McGREGOR


Book ID
114719081
Publisher
John Wiley and Sons
Year
1990
Tongue
English
Weight
692 KB
Volume
33
Category
Article
ISSN
0300-0664

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Antiparkinsonian activity of a non-ergot
✍ Dr. W. Poewe; G. Luef; B. Kleedorfer; M. Emre 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 255 KB

## Abstract Six patients with fluctuating Parkinson's disease received single rising oral doses of the nonergot dopamine agonist CV 205‐502 in an open experimental study. Doses of 0.5 mg produced antiparkinsonian effects of comparable intensity but longer duration than 200 mg of L‐DOPA. CV 205‐502,